Cell Impact has been awarded gold medal by EcoVadis
KARLSKOGA, Sweden, Nov. 11, 2025 /PRNewswire/ -- Last year, Cell Impact was…
Hyundai Motor Group and Pyeongtaek City Collaborate to Advance CarbonNeutral Hydrogen Port Development
Hyundai Motor Group signs a multilateral MoU with Pyeongtaek City and key…
Cell Impact and thyssenkrupp Automation Engineering have entered a cooperation agreement
KARLSKOGA, Sweden, Nov. 6, 2025 /PRNewswire/ -- Cell Impact and thyssenkrupp Automation Engineering have…
Legend Biotech Announces 10 Presentations at the 67th American Society of Hematology (ASH) Annual Meeting
Two oral and seven poster presentations further support the CARVYKTI® research in…
Cellectis to Report Third Quarter Financial Results on November 7, 2025
NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext…
Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting
SOUTH SAN FRANCISCO, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc.…
Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in Asia
TOKYO & HAYWARD, Calif.--(BUSINESS WIRE)--Taiho Pharmaceutical Co., Ltd. (“Taiho”) and Arcus Biosciences,…
Subcutaneous RYBREVANT(amivantamab) delivers promising 45 percent overall response rate with median duration of response of 7.2 months in recurrent or metastatic head and neck cancer
Responses were rapid and durable, and tumour shrinkage was observed in 82…
Precede Biosciences Presents New ESMO 2025 Data Demonstrating Its Liquid Biopsy Platforms Ability to Resolve Target Expression and Molecular Subtypes in Small Cell Lung Cancer
Small cell lung cancer (SCLC) accounts for 15% of all lung cancers…
HUTCHMED Highlights FRUSICA-2 Registration Trial Data to be Presented at the 2025 ESMO Congress
The fruquintinib and sintilimab combination demonstrated significant PFS improvements in advanced renal…